Latest Boehringer Ingelheim Stories
RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S.
Nation’s Premier Annual Physical Activity and Hispanic Family Health Celebration – Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH, a German pharmaceutical company, recently announced a settlement for approximately 4,000 claims related to injuries and deaths caused by the blood thinner Pradaxa.
German drugmaker Boehringer Ingelheim has offered to settle almost 4,000 Pradaxa lawsuits in the United States.
German pharmaceutical company Boehringer Ingelheim GmbH has agreed to settle nearly 4,000 claims against the drug company for injuries and deaths caused by the blood thinner Pradaxa.
BURLINGTON, ON, June 19, 2014 /CNW/ - Results from a Phase III 52 week study, show tiotropium (delivered via Respimat(®)*)5µg, a once-daily long-acting anticholinergic bronchodilator, is efficacious
-- No additional clinical trials requested by the FDA RIDGEFIELD, Conn. and INDIANAPOLIS, June 17, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
-- In a two-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in A1C (blood glucose), body weight and blood pressure compared with glimepiride as add-on
- For those taking metformin, empagliflozin/linagliptin combination tablet showed statistically significant reductions in blood glucose vs.
As Flood Law Group continues to investigate Pradaxa lawsuits, the company Boehringer Ingelheim has just paid $650 million to settle thousands of lawsuits against the drug company, according to
- A poem in which the author retracts something said in an earlier poem.